Overview
X-linked hypohidrotic ectodermal dysplasia (XLHED), also known as Christ-Siemens-Touraine syndrome, is the most common form of ectodermal dysplasia. It is caused by pathogenic variants in the EDA gene located on the X chromosome, which encodes the protein ectodysplasin A. This protein plays a critical role in the development of ectodermal structures during embryonic life, including hair, teeth, and sweat glands. Because of its X-linked recessive inheritance, males are typically more severely affected, while female carriers may show mild or variable features. The hallmark clinical triad of XLHED includes hypohidrosis (reduced or absent sweating due to fewer or absent eccrine sweat glands), hypotrichosis (sparse, thin, and lightly pigmented scalp and body hair), and hypodontia or oligodontia (missing teeth, with those present often being conical or peg-shaped). The inability to sweat properly can lead to life-threatening hyperthermia, particularly in infants and young children, as the body cannot regulate temperature effectively. Affected individuals may also have characteristic facial features including frontal bossing, a depressed nasal bridge, prominent lips, and periorbital wrinkling and hyperpigmentation. Dry skin, eczema-like rashes, and reduced mucous gland secretions affecting the eyes, airways, and gastrointestinal tract are also common. Currently, management of XLHED is primarily supportive and symptomatic. Temperature regulation strategies are essential, including avoidance of overheating, access to cooling devices, and environmental modifications. Dental management typically involves early prosthetic rehabilitation with dentures or dental implants to improve feeding, speech, and appearance. Artificial tears and nasal saline may be used for dryness of the eyes and airways. An investigational prenatal and neonatal treatment with a recombinant replacement protein (ER004) targeting the EDA pathway has shown promise in clinical trials, but is not yet approved for routine clinical use. Genetic counseling is recommended for affected families.
Also known as:
Clinical phenotype terms— hover any for plain English:
X-linked recessive
Carried on the X chromosome; typically affects males more than females
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for X-linked hypohidrotic ectodermal dysplasia.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for X-linked hypohidrotic ectodermal dysplasia at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to X-linked hypohidrotic ectodermal dysplasia.
Community
No community posts yet. Be the first to share your experience with X-linked hypohidrotic ectodermal dysplasia.
Start the conversation →Latest news about X-linked hypohidrotic ectodermal dysplasia
No recent news articles for X-linked hypohidrotic ectodermal dysplasia.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about X-linked hypohidrotic ectodermal dysplasia
What is X-linked hypohidrotic ectodermal dysplasia?
X-linked hypohidrotic ectodermal dysplasia (XLHED), also known as Christ-Siemens-Touraine syndrome, is the most common form of ectodermal dysplasia. It is caused by pathogenic variants in the EDA gene located on the X chromosome, which encodes the protein ectodysplasin A. This protein plays a critical role in the development of ectodermal structures during embryonic life, including hair, teeth, and sweat glands. Because of its X-linked recessive inheritance, males are typically more severely affected, while female carriers may show mild or variable features. The hallmark clinical triad of XLH
How is X-linked hypohidrotic ectodermal dysplasia inherited?
X-linked hypohidrotic ectodermal dysplasia follows a x-linked recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does X-linked hypohidrotic ectodermal dysplasia typically begin?
Typical onset of X-linked hypohidrotic ectodermal dysplasia is neonatal. Age of onset can vary across affected individuals.
Which specialists treat X-linked hypohidrotic ectodermal dysplasia?
25 specialists and care centers treating X-linked hypohidrotic ectodermal dysplasia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.